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Abstract  
Introduction: Adolescents and young adults (AYAs) diagnosed with cancer between ages 15-39 
years may harbour germline variants associated with cancer predisposition. Such variants represent 
putative therapeutic targets, as may somatic variants in the tumour. Germline and tumour molecular 
profiling is increasingly utilised to facilitate personalisation of cancer treatment in such individuals.  
Aim: Considering AYAs with advanced solid tumours managed in a specialist drug development unit 
(DDU), the aims of this study were to investigate the use and impact of:  
1. Germline genetic assessment  
2. Tumour molecular profiling  
Methods: AYAs treated in the DDU at the Royal Marsden Hospital between 2002 and 2016, were 
identified from departmental databases. Data regarding clinicopathological features, clinical 
assessments, germline and tumour genetic testing were retrieved by chart review. 
 
Results: The study cohort included 219 AYAs. Common cancer types included sarcoma (41, 19%); 
cervical (27,12%); breast (25; 11%); ovarian (23,11%) and colorectal (21,10%) cancers. Germline 
testing was undertaken in 34 (16%) patients, 22 of whom carried a pathogenic variant. Using current 
testing criteria, an additional 32 (15%) would be eligible for germline testing based on their personal 
history of cancer alone. Tumour testing was undertaken in 46 (21%) individuals. Somatic mutations 
were commonly identified in TP53 (12,31%), PIK3CA (8,18%); KRAS (4, 9%) and MET (4,9%).  
Discussion: A significant proportion of AYAs with advanced cancer have targetable somatic or 
germline mutations. Consideration of familial risk factors, and inclusion of germline testing where 
appropriate can complement tumour testing to optimize patient management, and inform 
management of at-risk relatives.  
 
  
Introduction 
 
The aim of phase I clinical trials is to determine the safety and tolerability of experimental agents in 
humans(1). Because of the unpredictable side effect profile and indeterminate efficacy of these 
agents, the majority of patients referred for consideration of such trials generally have advanced 
stage, heavily pre-treated tumours, or rare tumours with a paucity of available standard therapies. To 
fulfil eligibility criteria for such trials, patients must be of acceptable medical fitness (ECOG1 0 or 1) 
(2)), such that they have enough physiological reserve to cope with unexpected side effects. The 
patient population of phase I units is therefore enriched for younger patients, despite the relative 
rarity of cancer in individuals under the age of 40. Other factors are also considered in determining 
eligibility for phase I trials, including previous therapies and current medications and co-morbidities. 
Although the aim of the Phase I trial is to determine safety of experimental agents, patients are 
preferentially allocated to trials with best predicted likelihood of efficacy based on pre-clinical 
evidence, given that patient outcomes are known to be better when therapy is targeted (3-5). 
Molecular characterisation of tumours by sequencing or by immunohistochemistry may inform 
decision-making with respect to allocation to a trial of a targeted agent, immunotherapy or anti-
angiogenic agent depending on the molecular defect identified(6, 7). As genomic technologies have 
improved, and become more affordable(8), the methods by which this molecular characterisation can 
be routinely undertaken have changed dramatically in our institution, moving from hotspot 
mutational analysis by PCR to sequencing by next generation technologies using multi-gene panels. 
Our panels have also expanded over time to reflect increases in the size of the portfolio of targeted 
agents under investigation in our unit. The panel currently in use in our unit includes 113 “DNA 
damage repair” genes, including tumour suppressor genes such as BRCA1, BRCA2 or mismatch repair 
genes.  
                                                          
1
 ECOG:  Eastern Cooperative Oncology Group 
Individuals diagnosed with cancer between the ages of 15 and 39 are referred to as “adolescents and 
young adults (AYAs)(9). Cancers occurring in this cohort may include paediatric cancers occurring at 
unexpectedly older ages, or cancers of adulthood occurring at unexpectedly young ages(10-12). Such 
phenomena are characteristic of inherited cancer predisposition syndromes. Certain cancer types 
(13)occurring in this age group are also strong predictors of an underlying germline defect. The 
approximate likelihood of identifying a pathogenic mutation in TP53 in an AYA with an adrenocortical 
cancer, for example, is 13%(14), which is lower than the probability of identifying a mutation in a child 
with the same cancer (50-80%)(15-17), but over twice that of older adults (5.8%) (18). The 
characteristic cancer occurring in individuals with CDH1 mutations is diffuse gastric cancer, and the 
mean age of diagnosis in affected individuals is 38-40 years(19, 20). The association between high 
grade serous ovarian cancer and triple negative breast cancer with BRCA1/BRCA2 mutations is well-
established(21-23), and the likelihood of detecting a mutation in one of these genes in an affected 
individual is inversely proportional to the age at diagnosis. For this reason, in our institution, germline 
genetic testing is offered to individuals diagnosed with these and other certain types of cancer at ages 
younger than 40 years, irrespective of family history (Table 1). For other tumour types, tumour-based 
immunohistochemical analysis is recommended. In 2017, the NICE guidelines were updated to include 
a recommendation that all individuals diagnosed with colorectal cancer should have analysis of their 
tumour by IHC for mismatch repair proteins, or microsatellite stability testing, to guide further testing 
for Lynch syndrome(24). In our institution, routine IHC is also performed on all endometrial cancers 
for the same purpose.  
We conducted a study of AYA patients undergoing phase I clinical trials at the Drug Development Unit, 
Royal Marsden Hospital UK. One aim of this study was to investigate the proportion of individuals in 
this cohort with inherited cancer predisposition syndromes, and to identify how many additional 
individuals in this cohort would be eligible for germline investigations using current testing criteria. A 
second aim of this study was to examine the utility of germline and somatic testing in determining 
trial allocation in this patient cohort.  
Methods  
Germline Genetic Assessment  
In recent years, germline genetic testing at our institution has been performed using the Illumina 
TruSight cancer predisposition gene panel. After library preparation, sequencing is performed on the 
Illumina HiSeq2500. Although all genes on the panel are sequenced, only data pertaining to the genes 
of interest according to the clinical request form are analysed. Sequencing data is analysed using a 
bespoke pipeline. Rare and/or pathogenic variants are confirmed by Sanger sequencing or Multiplex 
Ligation-dependent Probe Amplification (MLPA)(25). Testing in other units utilises similar next 
generation sequencing technology. Prior to the availability of next generation sequencing, sequencing 
of single genes was generally performed by Sanger Sequencing and MLPA. Currently, 90% of results 
from diagnostic BRCA1 and BRCA2 analysis are reported within three weeks, and 80% of results from 
diagnostic analysis of other genes within four weeks(26).  
Somatic Genetic assessment  
Testing of tumours for potentially targetable mutations has been undertaken in our unit since 2011, 
commencing initially with testing of tumours for recurrent hotspot mutations in known driver genes, 
followed by sequencing of limited numbers of genes, and moving more recently to next generation 
sequencing of tumours using multi-gene panels. Tumours from twenty-eight patients were analysed 
using a 48-gene TruSeq® Amplicon Cancer Panel, and tumours from eleven patients were analysed 
using a custom-designed 113-gene “DNA damage repair” panel. Tumours from seven other patients 
were tested using multi-gene panels, but reporting of results was limited uniformly to ATM, BRAF, 
EGFR, HRAS, KRAS, NRAS, PIK3CA, and TP53, and variably to other genes of interest depending on the 
cancer type. In addition, select patients underwent immunohistochemical assessment of PTEN and 
ATM. For the purposes of this study, only results from multigene panel testing were analysed. The 
selection of patient to whom somatic testing was offered was largely dependent on portfolio of trials 
available within the unit at the time of the patient referral. Tumour molecular characterisation was 
offered to those patients for whom eligibility for a trial depended on presence/absence of particular 
molecular aberrations. 
Compared to germline variants, where the American College of Medical Genetics have defined strict 
guidelines for determination of pathogenicity, there is a paucity of guidance with respect to classifying 
somatic variants. Sequencing data were analysed using a bespoke pipeline, and variants identified 
with frequency greater than 5% were reported. Variants were classified as “high”, “medium” or “low” 
impact depending on type of variant and impact on protein, and on evidence from Clinvar and 
COSMIC databases. All results were discussed at a multi-disciplinary meeting. Other factors in 
determining whether a variant might be considered a driver mutation included tumour type, 
frequency of the variant in the tumour relative to tumour content analysed, and published literature 
regarding the variant in question. Data to support/refute pathogenicity of the same variant in the 
germline was also considered.  
Phase I trial Allocation  
All patients referred for consideration of a Phase I trials undergo initial clinical review to determine 
overall fitness to proceed based on current performance status, past medical history, medications and 
previous treatment. All cases are discussed at a weekly Patient Allocation Meeting, where this 
assessment, and other factors, such as tumour type, results of germline and somatic assessment and 
available trial slots are considered. Ideally, patients with confirmed pathogenic variants in the 
germline or soma are allocated to trials investigating utility of agents targeting the gene in question or 
a key pathway in which it is involved. In the case that no available trial exists, or if no slot is available 
on an existing trial, patients are allocated to the next best available trial depending on tumour type 
and patient factors. If rare variants of uncertain significance were identified in genes in which driver 
mutations were known to be associated with the tumour of interest, and if a trial using a targeted 
agent was available, cases were discussed with trial sponsors to determine patient eligibility.   
Results 
Patient Characteristics 
Two hundred and nineteen patients diagnosed with cancer between the ages of 15 and 39 were 
referred to the Drug Development Unit in the Royal Marsden Hospital during the study period, 
including 139 (63%) females and 80 (37%) males. The median age of patients was 32 (15-39). The 
most common cancer type affecting these patients was sarcoma (n=41, 19%, Table 2), of which the 
most common subtype was Ewing (n=14, 34%, Table 3). Sarcoma was the most common cancer type 
in males (25, 31%), followed by colorectal (n=13, 16%), while the most common cancers in females in 
this cohort were cervical (n=27, 19%), breast (n=25, 18%) and ovarian (n=22, 16%, Table 2). Most 
patients had undergone at least one line of systemic therapy in the adjuvant setting before 
consideration of a phase I clinical trial (Table 4), but the majority had a relatively short interval 
between diagnosis and referral for consideration of a phase I agent (Median time to referral 29 months 
(1-237), Table 4). 
Family History of Cancer  
In 81 (37%) individuals, no family history information was documented in either the patient’s referral 
documents or clinical notes. Twenty-four patients were noted to have a positive family history 
including a first degree relative with cancer. In ten cases, the positive family history was of a cancer 
with a potentially shared genetic aetiology. Forty-two patients had at least one second-degree 
relative with cancer, 19 of whom had a cancer with potentially shared genetic susceptibility.  The 
family history of 40 individuals in this cohort was deemed “non-contributory” in the clinical notes, but 
no detail was given as to whether the information sought was limited to first degree relatives, or 
whether a history of other cancers was present in the family.   
Germline Genetic Assessment 
Thirty-four patients (16%) were documented to have had germline genetic testing, of whom 22 were 
reported to have pathogenic variants (Table 5). Pathogenic variants were most commonly reported in 
BRCA1 (n=15) or BRCA2 (n=3), in eight patients with ovarian cancer and ten patients with breast 
cancer (Table 6). In 12 cases, genetic reports were not available for review, as they had not been 
provided at the time of patient referral, and were not actively requested.  
One variant of uncertain significance in BRCA2 (c.9205T>C; (p.Cys3069Arg)) was detected in a single 
patient diagnosed with hormone receptor and HER2-receptor-positive breast cancer at 23 years of 
age. It was not documented that TP53 analysis had been undertaken in this individual.  
One patient with early-onset Triple Negative breast cancer had undergone predictive testing for a 
known familial BRCA2 mutation, in advance of her own diagnosis, but unfortunately was not referred 
for full diagnostic testing subsequently.   
The majority of genetic testing was undertaken after formal consultation with a genetic specialist. 
Three patients had analysis of BRCA1 and BRCA2 as part of the mainstreaming genetic testing 
pathway(27, 28). Using current guidelines, an additional eighteen patients (10 breast, 8 non-mucinous 
ovarian) would now qualify for mainstreamed BRCA1/BRCA2 analysis in our institution.  One of these 
individuals had been assessed by a clinical geneticist at the time of her diagnosis, but did not fulfil 
testing criteria at the time of her review, and died before criteria for testing were loosened. 
Two other patients with breast cancer were reported to have inherited cancer predisposition 
syndromes, one with Cowden syndrome and another with type I Neurofibromatosis (NF1). Two other 
individuals with NF1 were included in this cohort, both of whom were diagnosed with malignant 
peripheral nerve sheath tumours. Two patients with Familial Adenomatous Polyposis (FAP) were also 
referred for consideration of Phase I trials, one of whom was diagnosed with colorectal cancer, and 
the other with a desmoid tumour. One patient with Von Hippel Lindau syndrome was assigned to a 
Phase I trial after developing metastatic clear cell cancer of the kidney. Uninformative germline 
testing of RET was undertaken in one patient with medullary thyroid cancer. MUTYH analysis was 
undertaken in one patient with early-onset mismatch repair-proficient colorectal cancer. 
Uninformative results were obtained from a multigene panel including CDKN1B, VHL, NF1 and MEN1 
in a patient with thymic neuroendocrine tumour. One patient with early-onset endometrial cancer 
underwent formal genetic assessment, tumour immunohistochemical assessment of mismatch repair 
proteins (MMR IHC) and germline FH (Fumarate Hydratase) testing. No underlying genetic defect was 
identified. MMR IHC was also performed on the tumours of two patients with early-onset colorectal 
cancer, which was normal in both cases. No further genetic assessment was undertaken in these 
individuals. Using current guidelines (29), the seventeen other patients in this series with colorectal 
cancer that did not have any such investigations performed should have, at least, MMR IHC or 
microsatellite instability of their tumours to out-rule Lynch syndrome. In our centre, the other young 
patient with endometrial cancer would also have MMR IHC analysis under contemporary institutional 
practice (Table 5).  
Three patients in this series had more than one primary cancer, including one individual with 
adrenocortical cancer aged 34 and secondary AML, one patient with breast cancer at 37 and previous 
history of Wilms’ tumour aged 12; neither of whom were referred for clinical genetics assessment, 
and one patient with metastatic olfactory aesthesioneuroblastoma with past medical history of 
Hodgkin’s lymphoma who was referred for genetics consultation, but died while awaiting an 
appointment.  
Somatic Genetic assessment  
In thirteen tumours tested using the 48-gene panel, no somatic variants with allele frequency greater 
than 5% (major variants) were identified. At least one major variant least 5% was identified in 26 
tumours (58%). Genes in which mutations were most commonly identified included TP53, KRAS, 
PIK3CA and MET (Figure 1). Increasing the panel size to 113-genes increased the yield of variants, but 
the majority of variants identified in genes that were not included on the 48-gene panel were either 
benign/passenger mutations, or pathogenic variants for which no targeted therapy currently exists.  
Use of genomic profiling in trial allocation  
Of eighteen patients with pathogenic BRCA1/BRCA2 variants, thirteen (72%) were allocated to a trial 
investigating utility of a Poly-ADP-ribose polymerase (PARP) inhibitor. Four other BRCA mutation 
carriers were allocated to trials investigating an agent involved in dsDNA damage response pathways. 
Considering all individuals (n=46) undergoing tumour molecular characterisation, nine were allocated 
to trials because of their underlying germline defect and seven assigned to trials of agents targeting 
identified somatic mutations or genes in a related pathway. Potentially actionable somatic mutations 
were identified in fifteen individuals, but at the time of their referral to the unit, there was either no 
suitable trial, or no slots available on a trial of interest. In three patients, allocation to a trial was not 
altered by tumour profiling, and assignation was on their tumour histology (Ewing sarcoma, n=2) or 
immunophenotype (HER2-positive breast cancer, n=1). In three patients, the crude number of 
mutations identified was considered a surrogate marker of high mutational load; and they were 
therefore assigned to trials of immunotherapy. For the other patients, no informative data were 
derived from germline or somatic genomic investigations.  
Discussion  
Cancer treatment in AYAs poses a unique set of challenges. Tumours in this cohort of individuals have 
been shown to demonstrate distinct biological behaviours compared to tumours of the same time 
occurring in the paediatric or older adult setting (9, 30-32). Furthermore, this cohort of individuals has 
unique psychosocial needs, and may have young children, siblings or parents for whom a familial risk 
of cancer may be relevant.  
Recognition of a heritable cause of cancer is essential to provide optimal care to individuals with 
cancer. Identification of germline defects may modify therapeutic decisions(33); for example, 
germline mutations in BRCA1 or BRCA2 tend to confer sensitivity to Platinum-based 
chemotherapy(23), while identification of a TP53 germline mutation may alter surgical decision-
making, or influence radiotherapy use or dose(34). In line with recent NICE guidelines (24), 
assessment of mismatch repair proteins by IHC is performed routinely in our institution on all 
colorectal cancers; and more recently, is also being routinely performed on all endometrial cancers. 
Identification of microsatellite instability or mismatch repair deficiency may help direct application of 
5-FU based chemotherapy in Duke’s B colon cancer(35), and may also indicate the presence of a 
germline mutation causing Lynch syndrome.  
In this cohort of unselected AYAs attending a phase I unit, investigations to confirm/out-rule an 
inherited cancer predisposition syndrome was, or would be undertaken using current guidelines in 89 
(41%) patients, based on their personal cancer history alone. In this cohort, usually only a limited 
family history was recorded. In 81 (37%), no family history information was documented in any of the 
patient’s referral documents or clinical notes, and in an additional 40 patients, the family history was 
deemed “non-contributory”, but may not have expressly included a 3-generation history. It is likely 
therefore that genetic investigations would have been indicated in an even greater proportion if a 
detailed family history was taken into account.  
In this particular cohort, the affected individuals had advanced cancer with poor prognoses. However, 
in AYAs with earlier stage cancer, the risk of second malignancies associated with a cancer 
predisposition syndrome is significant, and identification of a germline defect presents an opportunity 
to instigate prophylactic interventions. Furthermore, the significant risk to siblings, children and adults 
of these young individuals should also be considered, and preferably be discussed at an earlier stage 
of the disease). Consideration of a possible inherited germline defect in an individual in the palliative 
or experimental trial setting may provide the last opportunity for investigation in a family. In 
situations where an affected proband dies prior to genetic investigation, germline testing in the family 
is often impossible, as a negative result in an unaffected relative may not be reassuring to other 
individuals in the family. The results of this study suggest that germline genetic investigations should 
be routinely considered in AYAs with cancer, as the result may have a direct impact on management 
or allocation to a clinical trial.  
Previous studies have shown that tumour-based genetic testing can inadvertently unmask a germline 
mutation in 3-5% cases(36, 37). In our cohort, pathogenic variants were identified in BRCA1 and 
BRCA2 in tumours of two individuals with breast cancer. These results were not unexpected, as in 
both cases, the patients had previously been known to carry germline mutations. It is likely that, as 
more tumour testing is undertaken using the 113-gene panel, more variants in cancer susceptibility 
genes will be identified. It is important, therefore, to bear the possibility of unmasking a germline 
event in mind, particularly if the patient is young, or with a positive family history suggesting an 
inherited cancer predisposition.  At the present time, germline analysis to confirm constitutional 
status of a mutation in a particular gene in a patient without a positive family history may not be 
funded by the national health system (NHS), particularly if the mutation was identified in a tumour 
not known to be associated with germline mutations in that gene. To avoid this scenario, some units 
use germline DNA subtraction when interpreting their tumour sequencing results. This approach has 
the disadvantage of potentially missing targetable mutations. In our unit, and in most other oncology 
units, germline testing for the purpose of matched analysis is not routinely performed. All tumour 
results are discussed at a departmental clinical meeting. If any variant is suspected to be germline in 
origin, the case is discussed with the cancer genetics service, and germline testing undertaken, if 
appropriate. Due attention must be paid to the slight possibility of incidental results of this nature 
when consenting individuals for such testing, and concerns about how consent for such testing should 
be undertaken have been discussed within our unit and indeed internationally.  
Interpretation and classification of somatic variants is extremely challenging. Where classification of 
germline variants is guided by stringent guidelines such as those of the American College of Medical 
Genetics (ACMG)(38) and Association for Clinical Genetic Science (ACGS) (39), no robust classification 
system exists for somatic variants. In tumours, pathogenicity is not an immediate indicator that the 
mutation is driving the neoplastic process. This must be considered when a variant is identified in a 
tumour in a gene in which mutations have not previously been reported to drive the specific cancer. 
Clinical utility of the test is an important factor to consider before offering the test, as identification of 
variants of uncertain significance, or variants in genes of uncertain significance may not be 
informative, but may generate significant anxiety and additional clinical work. Interpretation of 
somatic variation is further complicated by mutation frequency – a suspected driver mutation with 
low mutation frequency may represent a driver mutation in only a subclonal population of cells, or 
may be a late passenger event. Tumour heterogeneity adds complexity to interpretation of tumour 
testing, and factors such as site of the biopsy (central or peripheral; primary or metastasis), previous 
treatments and potential secondary mutational events should be considered.  
Twelve patients were reported to have been identified as germline mutation carriers, but genetic 
reports had not been formally requested by our institution. We strongly recommend that genetic 
reports formally be reviewed, to confirm that the variant identified was pathogenic/likely pathogenic, 
and therefore clinically actionable. Genetic testing for NF1 is not routinely advocated, as this 
condition can be diagnosed on a clinical basis, and genetic testing is often uninformative if cDNA 
analysis has not been undertaken(40, 41). 
The relative frequency of different cancer types in our cohort was biased by availability of different 
trials over the study trial; the cohort was enriched for Ewing sarcoma because of an ongoing IGF1-
inhibitor trial; and for breast and ovarian cancers because of PARP-inhibitor studies.  
Conclusion  
Overall, 34 AYA patients (16%) did have germline genetic assessment, three (1%) had a confirmed 
genetic diagnosis, and two (1%) had tumour-based investigations. Using current testing criteria, an 
additional thirty-two (15%) of patients would qualify for a germline genetic test based on their 
personal history, and another 18 (8%) would have MMR IHC of their tumour. It is critical that heritable 
cancer predisposition be recognised in AYA patients in general, as it may have significant implications 
for the treatment and surveillance of the proband and his/her relatives. Ideally, diagnosis of a cancer 
predisposition syndrome should occur at an early stage in the patient’s treatment, to guide decision-
making. The phase I setting is not an ideal scenario in which to discuss genetic testing and 
implications for the family. In this setting, patients will be discussing clinical trials and tumour 
molecular profiling, and discussing germline testing as well may be confusing or overwhelming. The 
potential impact to the wider family may also cause psychological in a vulnerable individual dealing 
with a life-limiting illness with little therapeutic options. Conversely, the phase I setting may provide 
one of the last opportunities to offer germline testing to these patients, and by extension, their 
families. Overall 40% of this cohort would have qualified for germline genetic testing using today’s 
criteria based on their personal history alone, and it is likely that a greater proportion still would also 
qualify if accurate family history information was recorded. Involvement of a cancer geneticist 
routinely in the multidisciplinary care of this unique young cohort would help optimise the overall 
treatment of the patient and their family, particularly in cases where the proband has limited life 
expectancy.  
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 Tables 
Table 1: Indications for genetic testing in our unit 
Cancer  Gene  Indication for testing  
Breast  BRCA1/2 All Patients <45y  
TP53 All Patients <30 if BRCA1/2 testing 
uninformative  
Colorectal MMR IHC± germline 
analysis 
All patients 
APC/MUTYH CRC + ≥3 adenomatous polyps 
MUTYH CRC + 2 affected sibs  
Sarcoma  TP53 Rhabdomyosarcoma <5y  
Other sarcomas, depending on family 
history  
Adrenocortical cancer TP53 All patients 
Thyroid RET All medullary thyroid cancers  
PTEN Depends on clinical features 
Kidney  Renal Panel All patients <40y 
Paraganglioma/ 
Pheochromocytoma 
PGL/ 
Phaeochromocytoma 
panel 
All patients 
Ovarian BRCA1/2 All epithelial ovarian ca 
Stomach  CDH1 All patients <45y 
Endometrial MMR IHC± germline 
analysis 
All patients 
FH/PTEN  Depends on clinical features 
 
Table 2: Cancer types in male and female AYAs 
Cancer Type N(%) 
 Female (n=139) Male (n=80) Total 
(n=219) 
Sarcoma 16 (12) 25 (31) 41 (19) 
Cervix 27 (19) 0 27 (12) 
Breast 25 (18)  0 25 (11) 
Ovarian 22 (16)  0 22 (10) 
Colorectal 8 (6)  13 (16) 21 (10) 
Melanoma 9 (6) 7 (9) 17 (8) 
Brain 6 (4) 8 (10) 14 (6) 
Adrenocortical 5 (4) 2 (3)  7 (3) 
Cholangiocarcinoma 3 (2) 4 (5)  7 (3) 
Head and Neck 2 (1) 3 (4) 5 (2) 
Renal 2 (1) 3 (4) 5 (2) 
Germ cell 1 (1) 3 (4) 4 (2) 
HCC 1 (1) 3 (4) 4 (2) 
Lung 3 (2) 1 (1) 4 (2) 
MCUP 1 (1) 3 (4) 4 (2) 
Bladder 1 (1) 1 (1) 2 (1) 
Endometrial 2 (1) 0 2 (1) 
Others  4 (3) 4 (5)  8 (4) 
 
 
   
Table 3: Subtypes of sarcoma in male and female AYAs 
 Female  Male All patients 
Ewing Sarcoma Family 5 (31) 10 (40) 15 (37) 
Malignant Peripheral Nerve Sheath tumour 1 (6) 3 (12) 4 (10) 
Osteosarcoma 1 (6) 3 (12) 4 (10) 
Desmoplastic small round cell tumour 2 (13) 1 (4) 3 (7) 
Alveolar soft part sarcoma 1 (6) 1 (4) 2 (5) 
Chondrosarcoma 2 (13) 0 2 (5) 
Synovial Sarcoma 2 (13) 0 2 (5) 
Clear Cell Sarcoma 0 2 (8) 2 (5) 
Chordoma 0 1 (4) 1 (2) 
Fibrosarcoma 0 1 (4) 1 (2) 
Undifferentiated pleomorphic sarcoma 0 1 (4) 1 (2) 
Pulmonary Sarcoma 0 1 (4) 1 (2) 
Rhabdomyosarcoma 0 1 (4) 1 (2) 
Leiomyosarcoma 1 (6) 0 1 (2) 
Spindle cell sarcoma 1 (6) 0 1 (2) 
 16 25 41 
 
Table 4: Previous treatments and time to referral for different cancer types in AYAs 
 Median (Range) 
Cancer Type Number of previous lines of 
treatment 
Length of time between diagnosis and 
referral to DDU (months) 
Sarcoma  2 (0-6) 26 (2-164) 
Cervical  1 (0-3) 22 (6-60) 
Breast  2 (1-5) 52 (11-128) 
Ovarian 2.5 (0-6) 31.5 (6-237) 
Colorectal 2 (1-4) 23 (11-78) 
Melanoma 1 (0-3) 43 (1-110) 
Brain 2 (0-3) 55 (8-136) 
Adrenocortical 1 (1-2) 20 (8-52) 
Cholangiocarcinoma  2 (1-3) 17 (6-56) 
Head and Neck  1 (1-3) 13 (10-32) 
Renal 2 (0-2) 26 (17-47) 
Germ Cell Tumour 2 (2-3) 99 (9-201) 
Hepatocellular cancer  2 (1-4) 42.5 (5-151) 
Lung 2.5 (2-3) 12.5 (11-21) 
Bladder  1.5 (0-3) 19.5 (11-28) 
Endometrial 2.5 (2-3) 21 (19-23) 
Others 1 (1-5) 27.5 (13-70) 
Metastatic Cancer of 
unknown Primary 
2 (1-3) 11.5 (10-14) 
All cases 2 (0-6) 29 (1-237) 
 
  
Table 5: Germline genetic testing in AYAs 
 N Germline Genetic 
Assessment 
Undertaken 
Positive Result/ 
Clinical diagnosis 
Eligible for 
germline genetic 
testing based on 
personal history 
only using current 
guidelines 
Sarcoma 41 0 2 n/a 
Cervix 27 0 n/a 0 
Breast 25 14 12 12 
Ovarian 22 13 8 8 
Colorectal 21 2 1 0* 
Melanoma 17 0 n/a 0 
Brain 14 0 n/a 0 
Adrenocortical 7 0 n/a 7 
Cholangiocarcinoma 7 0 n/a 0 
Head and Neck 5 1 0 0 
Renal 5 1 1 5 
Germ cell 4 0 n/a 0 
Hepatocellular Carcinoma 4 0 n/a 0 
Lung 4 0 n/a 0 
Metastatic Cancer of 
Unknown Primary  
4 0 n/a 0 
Bladder 2 0 n/a 0 
Endometrial 2 1 0 0* 
Others 8 2 1 0 
Total  219 34 (16%) 25 (11%) 32 (15%) 
     
 N IHC analysis 
performed 
Loss of ≥1 MMR 
protein 
Additional 
patients eligible 
for IHC analysis 
Colorectal 20 3 (15%) 0 17 (85%) 
Endometrial 2 1 (50%) 0 1 (50%) 
*unless directed by IHC analysis 
 
 
Table 6: Germline variants identified in AYAs 
Gene Pathogenic Variant Number of patients Cancer in 
patient 
carrying 
variant  
BRCA1 c.427G>T p.Glu143Ter 1 Breast 
BRCA1 c.1505_1509delTAAAG p.Leu502Serfs 1 Ovarian 
BRCA1 c.3331_3334delCAAG p.Gln1111fs 2 Breast (1)  
Ovarian (1) 
BRCA1 c.3756_3759delGTCT  p.Ser1253Argfs 1 Ovarian 
BRCA1 c.4327C>T p.Arg1443Ter 1 Breast 
BRCA1 c.4574_4575delAA  p.Gln1525Argfs 1 Ovarian 
BRCA1 c.5266dupC_p.Gln1756ProfsX74) p.Gln1756Profs 1 Breast 
BRCA1 c.5278-1G>T p.? 1 Breast 
BRCA1 Duplication Exon 13 p.? 1 Breast  
PTEN Unknown, no report available for review 1 Breast  
APC Unknown, no report available for review 2 Colorectal (1) 
Desmoid (1) 
VHL Unknown, no report available for review 1 Kidney 
BRCA1 Unknown, no report available for review 5 Ovarian (4) 
Breast (1) 
BRCA2 Unknown, no report available for review 3 Breast (3) 
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